Immune checkpoint inhibitors, that is, antibodies blocking cytotoxic T-lymphocyte associated protein 4 (CTLA-4), programmed cell death 1 (PD-1) as well as its ligand PD-L1, have been approved by regulatory agencies around the world to treat multiple human cancer types (1). Here, PDCD1 is linked to cancer.